Market Overview

Is BioMarin A Buy Ahead Of This Important Data Release?

Is BioMarin A Buy Ahead Of This Important Data Release?

In a report published Monday, Leerink analyst Joseph P. Schwartz reiterated an Outperform rating and price target of $136 on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). The analyst believes that the stock's offers a positive risk/reward profile heading into the release of the BMN-111 data.

The analyst expects a 25 percent probability of success for the drug candidate, based on the positive preclinical data, as well as its mechanism of action, which was offset by the limited visibility into the impact on achondroplasia patients. "The major unknown is whether BMRN can find a dose which is effective and does not cause excessive symptomatic hypotension," Schwartz stated.

At the same time, the analyst expects the efficacy data from BMN-111's Phase 2 dose escalation study in achondroplasia to provide limited information. "Due to the small size and short duration of the study we believe that more meaningful height velocity improvements are likely to be seen than bone growth ratio improvements (so-called anthropomorphic benefits, which clinicians believe are more important for their patients' health). However, the former may be considered a rough surrogate for the likelihood of improving the latter with chronic treatment," the Leerink report said.

BioMarin targets a minimum improvement of 50 percent in height velocity, which the analyst believes would be a "relatively small addition in stature" of a mere 2cm per year. Given this low target and the "very impressive" animal data, the analyst expressed optimism that the trial would meet its endpoint.

However, the Leerink report also added that "although KOLs that we have spoken with believe that as little as a 10-25 percent enlargement in a patients' spinal canal aperture could translate into a significant health improvement for their patients who often have many physical complications and require many surgeries as a result."

The analyst now expects a 25 percent probability of BMN-111 being launched in 2018 and achieving peak sales of $1 billion per year.

Latest Ratings for BMRN

Apr 2019MaintainsOutperformOutperform
Apr 2019ReinstatesOutperform
Jan 2019DowngradesMarket OutperformMarket Perform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Joseph Schwartz LeerinkAnalyst Color Previews Reiteration Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (BMRN)

View Comments and Join the Discussion!

Latest Ratings

CHNGInitiates Coverage On19.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Morning Market Update: Markets Open Lower; CVS Health To Acquire Target's Pharmacy Business for $1.9B

Wunderlich Downgrades Two Harbors Investment To Hold